Joined: 8/13/2019
Posts: 12
|
http://www.t3dtherapeutics.com/lead-product-candidate-t3d-959/
Interested in your thoughts about this new release?
Thanks,
Pattie
|
Joined: 2/17/2019
Posts: 379
|
Pretty sure that's a Lane question.
Here's a bit of the text:
About T3D-959
T3D-959 is an investigational new drug candidate and is not approved for any indication in any markets.
T3D-959 Mechanism of Action
T3D-959 activates two nuclear receptors that are central regulators
of normal glucose and lipid metabolism in the brain. T3D-959 is
orally-delivered as a once-a-day medicine.
T3D-959 is the first PPAR delta-activating compound to be developed
for the treatment of Alzheimer’s disease (AD). Uniquely, this drug also
activates PPAR gamma, albeit at 15-fold lower potency, which may provide
potential additive or synergistic effects in regulating dysfunctional
brain glucose energy and lipid metabolism in AD.
Both PPAR delta and PPAR gamma targets are central regulators of
glucose and lipid metabolism. Agonism (activation) of both receptors
maintains metabolic homeostasis in similar and different ways. PPAR
delta is highly expressed throughout the central nervous system (CNS)
and enriched in areas of the brain involved in energy homeostasis, e.g.
the mediobasal hypothalamus.
|
Joined: 12/12/2011
Posts: 5176
|
Many good studies being posted on these boards these days but I am slow to catch up.
This article discusses some of the potential benefits of PPAR activation for Alzheimer's disease.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2077704/
One of the pathways by which PPAR activation contributes to neuroprotection is the phosphatidyinositol 3-kinase/Akt pathway, but this pathway is damaged in Alzheimer's disease.
|